How accurately do general practitioners and students estimate coronary risk in hypercholesterolaemic patients?

Primary Health Care Research and Development

Volumn 5, Issue 2, 2004, Pages 145-152

  Backlund, Lars ^a   Bring, Johan ^b   Strender, Lars Erik ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STATISTICON AB   (Sweden)

Author keywords

guidelines; hypercholesterolaemia; hyperlipidaemia; primary health care; risk assessment

Indexed keywords

EID: 85011482701     PISSN: 14634236     EISSN: 14771128     Source Type: Journal    
DOI: 10.1191/1463423604pc179oa     Document Type: Article

References (27)

1. Alderman, M.H. 1995: Quantifying cardiovascular risk in hypertension. Hypertension 13 519–527.
2. Alderman, M.H. 1996: Absolute cardiovascular risk: the basis for deciding to treat. American Journal of Nephrology 16, 182–189.
3. Anderson, K.M., Wilson, P.W.F., Odell, P.M. and Kannel, W.B. 1991: An updated coronary risk profile. A statement for health professionals. Circulation 83, 356–362.
4. Backlund, L., Danielsson, B., Bring, J. and Strender, L-E. 2000: Factors influencing GPs’ decisions on the treatment of hyper-cholesterolaemic patients. Scandinavian Journal of Primary Health Care 18, 88–93.
5. Berglund, G., Eriksson, K., Israelsson, B., Kjellstrom, T., Lindgarde, F., Mattiasson, I., Niisson, J., A. and Stavenow, L. 1996: Cardiovascular risk groups and mortality in an urban Swedish male population: the Malmo preventive project. Journal of Internal Medicine 239, 489–497.
6. Bjerrum L., Larsen J. and Kragstrup, J. 2001: Guidelines accompanied by changes in reimbursement. Scandinavian Journal of Primary Health Care 19, 158–162.
7. Friedman, P.D., Brett, A.S. and Mayo-Smith, M.F. 1996: Differences in generalists’ and cardiologists’ perceptions of cardiovascular risk and the outcomes of preventive therapy in cardiovascular disease. Annals of Internal Medicine 124, 414–421.
8. Gigerenzer, G. 1996: The psychology of good judgment: frequency formats and simple algorithms. Medical Decision Making 16, 273–280.
9. Grimshaw, J.M. and Russell, I.T. 1993: Effect of clinical guidelines on medical practice: a systematic review of rigorous evaluations. Lancet 27, 1317–1322.
10. Grol, R., Dalhuijsen, J., Thomas S., in ‘t Veld C., Rutten, G. and Mokkink, H. 1998: Attributes of clinical guidelines that influence use of guidelines in general practice: observational study. British Medical Journal 317, 858–861.
11. Grover, S.A., Lowensteyn, I., Esrey, K.I., Steinert, Y., Joseph, L. and Abrahamowicz, M. 1995: Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. British Medical Journal 310, 975–978.
12. Hach U.I., Ramsay, L.E., Yeo, W.W., Jackson, P.R. and Wallis, E.J. 1999: Is the Framingham risk function valid for northern European populations? A comparison of methods for estimating absolute coronary risk in high risk men. Heart 81, 40-46.
13. Jonsson, B. 2001: Economics of drug treatment: for which patients is it cost effective to lower cholesterol? Lancet 358, 1251–1256.
14. Leaverton, P.E., Sorlie, P.D., Kleinman, J.C., Dannenberg, A.L., Ingster-Moore, L., Kannel, W.B. and Cornoni-Huntley, J.C. 1987: Representativeness of the Framingham risk model for coronary heart disease mortality: a comparison with a national cohort study. Journal of Chronic Disease 40, 775–784.
15. Lomas, J., Anderson, G.M., Domnick-Pierrre, K., Vayda, E., Enkin, M.W. and Hannah, W.J. 1989: Do practice guidelines guide practice? The effects of concensus statement on the practice of physicians. New England Journal of Medicine 321, 1306–1311.
16. Mansfield, C.D. 1995: Attitudes and behaviours towards clinical guidelines: the clinicians’ perspective. Quality in Health Care 4, 250–255.
17. Niknian, M., McKinlay, S.M., Rakovwski, W. and Carleton, R.A. 1989: A comparison of perceived and objective CVD risk in a general population. American Journal of Public Health 79, 1653–1654.
18. Prosser, L.A., Stinnett, A.A., Goldman, P.A., Williams, L.W., Hunik, M.G., Goldman, L. and Weinstein, M.C. 2000: Cost-effeftiveness of cholesterol-lowering therapies according to selected patient characteristics. Annals of Internal Medicine 132, 769–779.
19. No authors listed. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (45) 1994. Lancet 344, 1383–1389.
20. SBU - The Swedish Council on Technology Assessment in Health Care. Moderately elevated blood pressure 1995. Journal of Internal Medicine 238 (suppl), 737.
21. Shepherd, J., Cobbe, S., Ford, I., Isles, C., Lorimer, A., MacFarlane, P.W., McKillop, J.H. and Packard, C.J. 1995: Prevention of coronary heart disease with Pravastatin in men with hypercholesterolaemia. New England Journal of Medicine 333,1301-1306.
22. Simon, A., Megnien, J. and Levenson, J. 1997: Coronary risk estimation and treatment of hypercholesterolaemia. Circulation 96, 2449–2452.
23. Tape, T.G. and Wigton, R.S. 1989: Medical students’ and residents’ estimates of cardiac risk. Medical Decision Making 9, 170–175.
24. Wallis, E., Ramsay, L., Jackson, P., Yeo, W. and Williamson, R. 1997: Drug therapy for coronary heart disease: the Sheffield table. Lancet 350, 1852–1854.
25. Watkins, C., Harvey, I., Langley, C., Gray, S. and Faulkner, A. 1999: General practitioners’ use of guidelines in the consul- tation and their attitudes to them. British Journal of General Practice 49, 11–15.
26. van der Weijden, T., Grol, R. and Knottnerus, J.A. 1999: Feasibility of a national cholesterol guideline in daily practice. A randomized controlled trial in 20 general practices. International Journal for Quality in Health Care 11, 131–137.
27. Wood, D., DeBacker, G., Faegerman, O., Graham, I., Mancia, G. and Pyorala, K. 1998: Prevention of coronary heart disease in clinical practice. Summary of recommendations of the second joint task force of European and other societies on coronary heart prevention. European Heart Journal 80 1–10.